Data gathered: November 14
Alternative Data for Viking Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 55,000 | Sign up | Sign up | Sign up |
| Employee Rating | N/A | Sign up | Sign up | Sign up |
| Google Trends | 23 | Sign up | Sign up | Sign up |
| Patents | 15 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 9 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 106 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 28,748 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,624 | Sign up | Sign up | Sign up |
| Twitter Mentions | 384 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 34 | Sign up | Sign up | Sign up |
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
| Price | $53.57 |
| Target Price | Sign up |
| Volume | 3,800,000 |
| Market Cap | $6.75B |
| Year Range | $47.39 - $83.34 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?November 13 - Yahoo |
|
 |
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?November 12 - Yahoo |
 |
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting ® 2024November 12 - Investing.com |
 |
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024November 12 - Yahoo |
 |
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by Principal Financial Group Inc.November 12 - ETF Daily News |
 |
Is Viking Therapeutics a Buy on the Dip?November 10 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 110,000 | 14M | -14M | -25M | -36M | -0.220 |
| Q2 '24 | 28,000 | 10M | -10M | -22M | -34M | -0.200 |
| Q1 '24 | 0 | 10M | -10M | -27M | -34M | -0.260 |
| Q4 '23 | 110,000 | 8.8M | -8.7M | -25M | -29M | -0.250 |
| Q3 '23 | 0 | 8.9M | -9M | -23M | -27M | -0.230 |
Insider Transactions View All
| MACARTNEY LAWSON filed to sell 47,965 shares at $68.7. November 8 '24 |
| ZANTE GREG filed to sell 149,366 shares at $81.4. October 28 '24 |
| ZANTE GREG filed to sell 158,539 shares at $79.8. October 28 '24 |
| ZANTE GREG filed to sell 150,572 shares at $80.7. October 28 '24 |
| ZANTE GREG filed to sell 203,496 shares at $76.9. October 28 '24 |
Similar companies
Read more about Viking Therapeutics (VKTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Viking Therapeutics?
The Market Cap of Viking Therapeutics is $6.75B.
What is the current stock price of Viking Therapeutics?
Currently, the price of one share of Viking Therapeutics stock is $53.57.
How can I analyze the VKTX stock price chart for investment decisions?
The VKTX stock price chart above provides a comprehensive visual representation of Viking Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Viking Therapeutics shares. Our platform offers an up-to-date VKTX stock price chart, along with technical data analysis and alternative data insights.
Does VKTX offer dividends to its shareholders?
As of our latest update, Viking Therapeutics (VKTX) does not offer dividends to its shareholders. Investors interested in Viking Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Viking Therapeutics?
Some of the similar stocks of Viking Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.